The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Primidone. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The metabolism of Paricalcitol can be increased when combined with Rifabutin. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The metabolism of Paricalcitol can be increased when combined with Rifampicin. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. Metolazone may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Indapamide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. Danazol may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat.